A 25-year-old man has been arraigned on a murder charge, accused of killing and then burying his brother in Allegan, Michigan.
Allegan-based Perrigo Co. (NYSE:PRGO) and Ireland’s Elan Corp. plc (NYSE:ELN) Friday announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan.
Perrigo Co. (NYSE: PRGO) announced that, in connection with its offer to purchase for cash its 2.950% Notes due 2023, it has received the requisite consents to amend the indenture governing the notes.
The Allegan generic drugmaker and store brand health products producer Perrigo Co. (NYSE: PRGO) Wednesday announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% and has notified Dow Pharmasciences, the owner of the New Drug Application, of its filing.
The generic prescription drug and store-brand health products maker Perrigo Co. (NYSE: PRGO) announced that its shareholders approved proposals related to its acuqisition of Ireland’s Elan Corp. plc at a special meeting Monday.
Perrigo Co. (NYSE: PRGO) announced that its board declared a quarterly dividend of 9 cents per share, payable Dec. 17 to shareholders of record on Nov. 29.
The Allegan generic pharmaceutical and store-brand health products maker Perrigo Co. Ltd., which moved its corporate registration to Ireland earlier this year, said it would offer debt totaling $2.3 billion with maturities in 2016, 2018, 2023 and 2043.
The generic pharmaceutical and store-brand helath products maker Perrigo Co. (NYSE: PRGO) Thursday reported net income of $111.4 million or $1.18 a share in the first fiscal quarter ended Sept. 28, up from $105.6 million or $1.12 a share in the first fiscal quarter a year earlier. Revenue was $933.4 million, up from $769.8 million a year earlier.
Perrigo Co. (NYSE: PRGO) announced that it has scheduled a shareholder meeting for Monday, Nov. 18 in connection with Perrigo’s proposed previously announced acquisition of Elan Corp. (NYSE: ELN).
Perrigo Co. (NYSE: PRGO) announced that it has received final approval for its abbreviated new drug application for nitroglycerin lingual spray, 400 mcg/spray, the generic equivalent to Nitrolingual Pumpspray.